Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these thera...

Full description

Saved in:
Bibliographic Details
Format: Electronic eBook
Language:English
Published: Cham : Springer International Publishing, 2018.
Edition:1st ed. 2018.
Series:Resistance to Targeted Anti-Cancer Therapeutics, 17
Subjects:
Cancer research.
Molecular biology.
ISBN:9783319751849
ISSN:2196-5501 ;
Online Access: Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Table of Contents:
  • Chapter 1 BTK inhibitors: focus on ibrutinib and similar agents
  • Chapter 2 BCL2 Inhibitors: insights into resistance
  • Chapter 3 Proteasome Inhibitors with a Focus on Bortezomib
  • Chapter 4 IMiD - immunomodulatory drug lenalidomide (CC-5013; Revlimid) in the treatment of lymphoma: Insights into clinical use and molecular mechanisms
  • Chapter 5 mTOR inhibitors, with special focus on temsirolimus and similar agents
  • Chapter 6 Inhibitors of the JAK/STAT pathway, with a focus on ruxolitinib and similar agents.

Similar Items